Abpro Holdings, Inc.

Abpro Holdings, Inc., trading under the ticker ACAB, is a biopharmaceutical company that reached the public markets through a SPAC merger, operating in the healthcare and life sciences sector. The company filed an 8-K with the SEC on November 8, 2024, under accession number 0001193125-24-253672, reflecting continued post-merger reporting obligations as a public entity. Abpro focuses on antibody engineering and therapeutic development, placing it within the broader biotech deal universe that SPACs have actively pursued in recent years. Investors and analysts tracking the company's evolution from blank-check vehicle to operating entity can sign up for full deal history, filing alerts, and sponsor data on SpacDesk.